Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
Details : Bicalutamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 29, 2021
Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bicalutamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 26, 2020
Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Bayer AG | Decipher Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Details : Bicalutamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2019
Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Bayer AG | Decipher Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Hoosier Cancer Research Network | Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bicalutamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2015
Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Hoosier Cancer Research Network | Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bicalutamide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence of Bicalutamide New Formulation in Japan
Details : ICI176,334-1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 15, 2011
Lead Product(s) : Bicalutamide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bicalutamide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Mucosal Absorption Study of Bicalutamide New Formulation
Details : ICI176,334-1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 15, 2011
Lead Product(s) : Bicalutamide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bicalutamide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence of ICI176,334-1 in Japanese Healthy Male Subjects
Details : ICI176,334-1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 12, 2011
Lead Product(s) : Bicalutamide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bicalutamide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Mucosal Absorption of ICI176,334-1
Details : ICI176,334-1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 12, 2011
Lead Product(s) : Bicalutamide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bicalutamide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Watson Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bicalutamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 08, 2010
Lead Product(s) : Bicalutamide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Watson Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
